Skip to content

Using EMR Data and AI to Develop a Passive Digital Marker to Predict Postoperative Delirium

Using EMR Data and AI to Develop a Passive Digital Marker to Predict Postoperative Delirium

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06216483
Enrollment
60
Registered
2024-01-22
Start date
2024-07-23
Completion date
2026-08-21
Last updated
2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium in Old Age

Brief summary

This study will be a pilot randomized controlled trial that will determine the effect of an indicator of delirium risk, which will be delivered either via a paper form or via the electronic medical record, on (1)postoperative delirium incidence; and (2)the development of long term cognitive decline and dementia.

Detailed description

Patients will be recruited from a large general, minimally invasive, colorectal, and oncologic, university-based surgical practice. English speaking individuals over the age of 65 with planned major abdominal surgery (encompassing abdominal wall, gastrointestinal and hepatobiliary procedures for benign and malignant diseases) will be screened for eligibility following an initial visit with their surgeon. Inclusion criteria will include a required inpatient stay for ≥ 24 hours following surgery and a scheduled preadmission testing and medical risk stratification visit with an internal medicine provider. Patients will be excluded if they have severe mental illness, hearing and visual impairment, alcohol intoxication or related delirium, central nervous disorder (e.g., stroke, traumatic brain injury), and pregnant or nursing status. Once enrolled, subjects will be randomized using a computer-generated scheme (permuted blocks of four and six) to the PDM or usual care, stratified according to type of surgery (hepatobiliary, gastrointestinal, abdominal wall).

Interventions

OTHERPDM Alert

passive digital marker (PDM) for postoperative delirium risk

Sponsors

Indiana University
Lead SponsorOTHER
National Institute on Aging (NIA)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

65 years old Planned inpatient major surgery requiring inpatient stay ≥ 1 day

Exclusion criteria

* Baseline cognitive impairment or a diagnosis of Alzheimer's Disease/Alzheimer's Disease and Related Dementias (AD/ADRD) * Alcohol or drug withdrawal * Prisoner status * Unable to communicate with research staff due to sensory impairments * Not fluent in English * Currently has a personal safety attendant

Design outcomes

Primary

MeasureTime frameDescription
Delirium incidence as measured by the 3D-CAMDaily during post-operative inpatient hospitalization through post-operative day 7The number of subjects diagnosed with delirium via the 3D-CAM questionnaire will be measured. The 3D-CAM is a brief verbal assessment tool that can be used to test patients and study participants for delirium via the Confusion Assessment Method (CAM). The 3D-CAM assessment is scored as either delirium present or delirium not present. Participants will be evaluated daily during the acute post-operative phase of the study (Post-Operative Days 0-7).
Delirium incidence as measured by the CAM ICUDaily during post-operative inpatient hospitalization through post-operative day 7The number of subjects diagnosed with delirium as assessed by the Confusion Assessment Method ICU will be measured. The CAM ICU is a tool used to assess delirium in adult ICU patients. CAM ICU scoring ranges from 0-7 with scores between 0-2 indicating no delirium, between 3-5 indicating mild to moderate delirium, and between 6-7 indicating severe delirium. Participants will be evaluated daily during the acute post-operative phase of the study (Post-Operative Days 0-7).
Delirium severity as measured by the CAM ICUDaily during post-operative inpatient hospitalization through post-operative day 7Delirium severity will be assessed via the Confusion Assessment Method ICU, a tool used to assess delirium in adult ICU patients. The CAM ICU is a tool used to assess delirium in adult ICU patients. CAM ICU scoring ranges from 0-7 with scores between 0-2 indicating no delirium, between 3-5 indicating mild to moderate delirium, and between 6-7 indicating severe delirium. Participants will be evaluated daily during the acute post-operative phase of the study (Post-Operative Days 0-7).

Secondary

MeasureTime frameDescription
Inpatient fallsDuring post-operative inpatient hospitalization through post-operative day 7The number of inpatient falls will be compared between groups. This data will be extracted from the participants' Electronic Medical Record.
Restraint UseDuring post-operative inpatient hospitalization through post-operative day 7Use of restraints will be compared between groups. This data will be extracted from the participants' Electronic Medical Record.
Sedative UseDuring post-operative inpatient hospitalization through post-operative day 7Sedative use will be compared between groups. This data will be extracted from the participants' Electronic Medical Record.
Use of personal safety attendantsDuring post-operative inpatient hospitalization through post-operative day 7Personal safety attendant use will be compared between groups. This data will be extracted from the participants' Electronic Medical Record.
Provider SatisfactionWithin 2-6 weeks following participant dischargeProvider satisfaction will be measured determined by a Simplified System Usability Scale (SSUS). The SSUS will be administered to providers within two weeks of the participant's discharge from the hospital, and providers will be asked to respond within 4 weeks of survey receipt. The SSUS yields a single number representing a composite measure of the overall usability of the system. Scores can range from 0 to 100, with higher scores indicating better usability.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026